JP2005537032A5 - - Google Patents

Download PDF

Info

Publication number
JP2005537032A5
JP2005537032A5 JP2004569756A JP2004569756A JP2005537032A5 JP 2005537032 A5 JP2005537032 A5 JP 2005537032A5 JP 2004569756 A JP2004569756 A JP 2004569756A JP 2004569756 A JP2004569756 A JP 2004569756A JP 2005537032 A5 JP2005537032 A5 JP 2005537032A5
Authority
JP
Japan
Prior art keywords
adzyme
substrate
catalytic domain
targeting moiety
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004569756A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005537032A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/026937 external-priority patent/WO2004019878A2/en
Publication of JP2005537032A publication Critical patent/JP2005537032A/ja
Publication of JP2005537032A5 publication Critical patent/JP2005537032A5/ja
Pending legal-status Critical Current

Links

JP2004569756A 2002-08-27 2003-08-27 アドザイムおよびその用途 Pending JP2005537032A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40651702P 2002-08-27 2002-08-27
US42375402P 2002-11-05 2002-11-05
US43000102P 2002-11-27 2002-11-27
PCT/US2003/026937 WO2004019878A2 (en) 2002-08-27 2003-08-27 Adzymes and uses thereof

Publications (2)

Publication Number Publication Date
JP2005537032A JP2005537032A (ja) 2005-12-08
JP2005537032A5 true JP2005537032A5 (cg-RX-API-DMAC7.html) 2006-10-19

Family

ID=31982336

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004569756A Pending JP2005537032A (ja) 2002-08-27 2003-08-27 アドザイムおよびその用途

Country Status (6)

Country Link
US (2) US20040081648A1 (cg-RX-API-DMAC7.html)
EP (1) EP1539941A4 (cg-RX-API-DMAC7.html)
JP (1) JP2005537032A (cg-RX-API-DMAC7.html)
AU (1) AU2003262937B2 (cg-RX-API-DMAC7.html)
CA (1) CA2497047A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004019878A2 (cg-RX-API-DMAC7.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
CA2416219C (en) 2000-07-11 2016-10-11 Research Corporation Technologies, Inc. Artificial antibody polypeptides
WO2003104418A2 (en) 2002-06-06 2003-12-18 Research Corporation Technologies, Inc. Reconstituted polypeptides
US20050074865A1 (en) * 2002-08-27 2005-04-07 Compound Therapeutics, Inc. Adzymes and uses thereof
US20060024289A1 (en) * 2002-10-02 2006-02-02 Ruggles Sandra W Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases
US7939304B2 (en) * 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
WO2004031733A2 (en) * 2002-10-02 2004-04-15 Catalyst Biosciences Methods of generating and screenign for porteases with altered specificity
US20080221029A1 (en) * 2002-10-31 2008-09-11 Regents Of The University Of Colorado Methods for treatment of thiol-containing compound deficient conditions
US7790762B2 (en) 2002-10-31 2010-09-07 National Jewish Health Compounds and methods for thiol-containing compound efflux and cancer treatment
US20040087527A1 (en) * 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
WO2005087947A2 (en) * 2004-03-09 2005-09-22 Meyer Pharmaceuticals Llc Bioengineered proteolytic enzymes with enhanced specificity for cytokine receptors
WO2005110453A2 (en) * 2004-04-12 2005-11-24 Catalyst Biosciences, Inc. Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1
US20090042780A1 (en) * 2004-05-20 2009-02-12 Acceleron Pharma Inc Modified TGF-Beta Superfamily Polypeptides and Related Methods
US7553810B2 (en) * 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
US20050281799A1 (en) 2004-06-16 2005-12-22 Glen Gong Targeting damaged lung tissue using compositions
US20050281740A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
US20050281739A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue using compositions
US7608579B2 (en) * 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
US20050281798A1 (en) * 2004-06-16 2005-12-22 Glen Gong Targeting sites of damaged lung tissue using composition
CA2570261C (en) 2004-07-08 2014-06-10 Pneumrx, Inc. Pleural effusion treatment device, method and material
ES2325344B1 (es) * 2004-11-02 2010-06-09 Univ Madrid Autonoma Inhibidores de angiogenesis multifuncionales y multivalentes.
US20080171067A1 (en) * 2007-01-17 2008-07-17 Immunomedics, Inc. Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites
AU2006264339A1 (en) * 2005-07-01 2007-01-11 Acceleron Pharma Inc. Lefty, Lefty derivatives and uses therof
WO2007030708A2 (en) * 2005-09-08 2007-03-15 Adnexus Therapeutics, Inc. Antimicrobial adzymes and uses thereof
WO2008048685A2 (en) * 2006-10-19 2008-04-24 Duke University Ox40 aptamers
CN101517086A (zh) 2006-07-21 2009-08-26 希乐克公司 生物质转化系统
AU2007325838B2 (en) 2006-11-22 2013-09-19 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
US7680553B2 (en) * 2007-03-08 2010-03-16 Smp Logic Systems Llc Methods of interfacing nanomaterials for the monitoring and execution of pharmaceutical manufacturing processes
WO2009002607A1 (en) * 2007-05-01 2008-12-31 Dana-Farber Cancer Institute, Inc. Compositions and methods for identifying transforming and tumor suppressor genes
EP2247615B1 (en) 2008-02-14 2014-07-30 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind egfr
AR071874A1 (es) 2008-05-22 2010-07-21 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
US20100099609A1 (en) * 2008-07-28 2010-04-22 Buck Institute For Age Research eAPP AND DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE
CN110187119B (zh) * 2008-10-31 2022-07-29 耶鲁大学 子痫前期检测和治疗的方法和组合物
CA3190837A1 (en) * 2009-01-15 2010-07-22 Glutagen Pty Ltd Compositions for the treatment of gluten intolerance and uses thereof
WO2011050263A2 (en) * 2009-10-23 2011-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Systemic immunosuppression in the treatment of age related macular degeneration and diabetic retinopathy
ITBG20120050A1 (it) * 2012-10-29 2013-01-28 Michele Mutti Proteina di fusione con attività proteasica e specificità degli anticorpi
US20190343963A1 (en) * 2016-04-22 2019-11-14 Medimmune Limited Conjugated protease targeting moieties
AU2017340387A1 (en) * 2016-10-04 2019-05-02 University Of Florida Research Foundation, Inc. Targeted effector proteins and uses thereof
WO2019075062A1 (en) 2017-10-11 2019-04-18 University Of Florida Research Foundation MODIFIED GAL-1 PROTEINS AND USES THEREOF
WO2019222296A1 (en) * 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
WO2020087051A1 (en) 2018-10-26 2020-04-30 University Of Florida Research Foundation, Incorporated Targeted chondroitinase abc fusion proteins and complexes thereof
US12577282B2 (en) 2019-02-28 2026-03-17 University Of Florida Research Foundation, Incorporated Galectin-1/ galectin-3 chimeras and multivalent proteins
WO2025114429A1 (en) * 2023-11-29 2025-06-05 Intract Pharma Ltd Transcytosing composition

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5811265A (en) * 1988-08-19 1998-09-22 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
EP0355068A3 (en) * 1988-08-19 1991-09-04 The General Hospital Corporation Recombinant hybrid immunoglobulin molecules and their use
WO1991012328A1 (en) * 1990-02-15 1991-08-22 Fowlkes Dana M Totally synthetic affinity reagents
US5961973A (en) * 1992-03-06 1999-10-05 Crea; Roberto Pathogen-targeted biocatalysts
CA2086165A1 (en) * 1992-04-09 1993-10-10 Paul P. Tamburini Diagnostic assay for alzheimer's disease based on the proteolysis of alzheimer's precursor protein
US5997861A (en) * 1994-10-31 1999-12-07 Burstein Laboratories, Inc. Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin
US6399355B1 (en) * 1995-06-07 2002-06-04 The Trustees Of Columbia University In The City Of New York Non-naturally occurring targeted lipolytic compounds and related compositions and methods
GB9618960D0 (en) * 1996-09-11 1996-10-23 Medical Science Sys Inc Proteases
DE19643314A1 (de) * 1996-10-21 1998-04-23 Boehringer Mannheim Gmbh Monoklonale Antikörper gegen das Epitop YPYDVPDYA, Verfahren zu deren Herstellung und Verwendung
US6406846B1 (en) * 1997-10-14 2002-06-18 David Whitcomb Method for determining whether a human patient is susceptible to hereditary pancreatitis, and primers therefore
US6159722A (en) * 1997-12-03 2000-12-12 Boehringer Mannheim Gmbh Chimeric serine proteases
US6627744B2 (en) * 1999-07-02 2003-09-30 Genencor International, Inc. Synthesis of glycodendrimer reagents
CA2412664A1 (en) * 2000-06-15 2001-12-20 Board Of Regents The University Of Texas System Regulatable, catalytically active nucleic acids
CN100400101C (zh) * 2000-08-17 2008-07-09 特里帕普股份公司 包含病毒唑的疫苗及其使用方法
US20030068792A1 (en) * 2000-12-14 2003-04-10 Yiyou Chen Targeted enzymes
AU2002342672A1 (en) * 2001-09-11 2003-03-24 Nascacell Gmbh Method for screening for inhibitors of protein/protein interaction and corresponding ribozymes

Similar Documents

Publication Publication Date Title
EP1730198B1 (en) Adzymes and uses thereof
AU2021219720B2 (en) Chromatography resin and uses thereof
AU2003262937B2 (en) Adzymes and uses thereof
KR100484084B1 (ko) 키메라성 폴리펩타이드, 이의 제조 방법 및 용도
US11584778B2 (en) Fusion protein with half-life extending polypeptide
CN105829542A (zh) 改进的重组多肽生产方法
JP2018524995A (ja) 抗体ドメイン融合タンパク質を含むヘテロマー
CN101914161B (zh) 抑制肿瘤生长的融合蛋白HGFα-Fc及其用途
EP1314780A1 (en) Collagen-binding hybrid polypeptide
EP1343909A2 (en) Methods for large scale protein production in prokaryotes
NZ335932A (en) Use of a peptide agent such as a diphosphorylated peptide to modulate the interactions between myosin and integrins
JPH05271291A (ja) 機能性ポリペプチド
WO2007030708A2 (en) Antimicrobial adzymes and uses thereof
US20250352618A1 (en) Methods of treating bronchopulmonary dysplasia
AU2002221815B2 (en) Methods for large scale production of recombinant DNA-derived tPA or K2S molecules
Ribó et al. Production of Human Pancreatic Ribonuclease inSaccharomyces cerevisiaeandEscherichia coli
RU2825102C2 (ru) Рекомбинантные белки с доменами ccn и слитые белки
TWI781415B (zh) 用於皮下注射之包含人類玻尿酸酶ph20變異體及藥物的醫藥組合物
JP2001526027A (ja) フィブリノーゲン変換酵素ハイブリド